# GENESTACK Compiler: Comprehensive Compounds Guide

## 1. Overview

The **GENESTACK Compiler Layer** takes inferred gene expression profiles and creates high-affinity intervention stacks. It evaluates individual compound mechanics, maps them to relevant biological pathways, optimizes dosages, and screens for conflicts before outputting the final protocol.

---

## 2. Compilation Rules

The Compiler operates on four core principles:

```
+─────────────────────────────────────────────────────────────────────────────+
|                         GENESTACK Compilation Pipeline                      |
+─────────────────────────────────────────────────────────────────────────────+

   [ Suboptimal Gene Expressions ]     [ Inferred Expression Levels ]
                      │                               │
                      └────────────────┬──────────────┘
                                       │
                                       ▼
                     +─────────────────────────────────+
                     |    Targeted Selection Engine     |
                     |  - Maps molecules to pathways   |
                     |  - Eliminates redundant options |
                     +────────────────┬────────────────+
                                      │
                                      ▼
                     +─────────────────────────────────+
                     |     Dynamic Dosage Scaling      |
                     |  - Caps maximum safe dose       |
                     |  - Calculates synergy bonus     |
                     +────────────────┬────────────────+
                                      │
                                      ▼
                     +─────────────────────────────────+
                     |    Cross-Module Risk Check      |
                     |  - Prevents contraindications   |
                     |  - Flags safety overrides       |
                     +────────────────┬────────────────+
                                      │
                                      ▼
                         [ Compiled Stack Protocol ]
```

### Core Pipeline Constraints

1. **Targeted Formulation**: Every compound in the stack maps directly to a suboptimal gene expression state or biomarker reading.
2. **Redundancy Elimination**: If a single compound can address multiple pathways at once, it is consolidated to optimize stack simplicity.
3. **Synergy Maximization**: Focuses on complementary mechanisms—such as combining a GH-releasing hormone analogue with a healing peptide—to maximize performance.
4. **Constraint Filtering**: Validates the stack against dynamic dosage boundaries and safety thresholds to prevent receptor burnout or pathway suppression.

---

## 3. Intervention Compounds Database

Below is the definitive reference matrix for the primary compound interventions included in the GENESTACK Compiler.

### 3.1 Therapeutic Peptides

#### BPC-157 — Body Protection Compound 157
- **Classification**: Synthetic pentadecapeptide
- **Biological Pathway**: Nitric oxide modulation, VEGFR2 activation
- **Expression Mapping**: `TNF-α` upregulated, `IL6` upregulated
- **Mechanism of Action**: Accelerates tissue repair through localized soft tissue remodeling and direct regulation of pro-inflammatory cytokines. BPC-157 works by promoting dynamic growth factor production in targeted areas without systemic risks.
- **Dynamic Baseline Range**: `200 - 300 mcg`, administered BID (twice daily).

#### CJC-1295 — Growth Hormone Releasing Hormone Analogue
- **Classification**: Synthetic GHRH peptide (with DAC variant)
- **Biological Pathway**: Growth Hormone / IGF-1 Axis stimulation
- **Expression Mapping**: `IGF1` downregulated
- **Mechanism of Action**: Binds to pituitary receptors to stimulate pulsatile GH release, avoiding the insulin resistance risks associated with synthetic hGH.
- **Dynamic Baseline Range**: `2.0 - 2.5 mg` weekly.

#### AOD-9604 — Anti-Obesity Drug Fragment
- **Classification**: Modified GH Fragment (hGH 176-191)
- **Biological Pathway**: Lipolysis stimulation, adipogenesis restriction
